JP2016512540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512540A5 JP2016512540A5 JP2016501545A JP2016501545A JP2016512540A5 JP 2016512540 A5 JP2016512540 A5 JP 2016512540A5 JP 2016501545 A JP2016501545 A JP 2016501545A JP 2016501545 A JP2016501545 A JP 2016501545A JP 2016512540 A5 JP2016512540 A5 JP 2016512540A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- benzodiazepine
- concentration
- antibody
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCC(C)(*)C(CC(N1CCCCCC(N[C@@](C(C)C)C(N[C@@](C)C(Nc(cc2)ccc2C(CC2C=Nc(cc3OCCCOc(cc(c4c5)N=CC(CC(c6ccc(*=CC)cc6)=C6)N6C4=O)c5OC)c4cc3OC)=CN2C4=O)=O)=O)=O)=O)C1=O Chemical compound CCCC(C)(*)C(CC(N1CCCCCC(N[C@@](C(C)C)C(N[C@@](C)C(Nc(cc2)ccc2C(CC2C=Nc(cc3OCCCOc(cc(c4c5)N=CC(CC(c6ccc(*=CC)cc6)=C6)N6C4=O)c5OC)c4cc3OC)=CN2C4=O)=O)=O)=O)=O)C1=O 0.000 description 6
- TWQIMWSQDICMSE-DGCIIGOYSA-N CC(C)[C@@H](C(N[C@@H](C)C(Nc(cc1)ccc1C(C[C@H]1C=Nc(cc2OCCCOc(cc(c3c4)N=C[C@H](CC(c(cc5)ccc5OC)=C5)N5C3=O)c4OC)c3cc2OC)=CN1C3=O)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(Nc(cc1)ccc1C(C[C@H]1C=Nc(cc2OCCCOc(cc(c3c4)N=C[C@H](CC(c(cc5)ccc5OC)=C5)N5C3=O)c4OC)c3cc2OC)=CN1C3=O)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O TWQIMWSQDICMSE-DGCIIGOYSA-N 0.000 description 2
- BOCHTVOJCHUPTR-DICHSLLOSA-N COc(cc1)ccc1C(C[C@H]1C=Nc(cc2OCCCOc(cc(c3c4)N=C[C@@H](CC(c(cc5)ccc5N)=C5)CN5C3=O)c4OC)c3cc2OC)=CN1C3=O Chemical compound COc(cc1)ccc1C(C[C@H]1C=Nc(cc2OCCCOc(cc(c3c4)N=C[C@@H](CC(c(cc5)ccc5N)=C5)CN5C3=O)c4OC)c3cc2OC)=CN1C3=O BOCHTVOJCHUPTR-DICHSLLOSA-N 0.000 description 2
- OPVXRHWKTYZKMG-LPYWLSHSSA-N C[C@](CC(C(C=C1)=CCC1(C)N)=C1)(C=Nc(c2c3)cc(OCCCOc(c(OC)c4)cc(N=C[C@H](C5)N6C=C5c(cc5)ccc5OC)c4C6=O)c3OC)N1C2=O Chemical compound C[C@](CC(C(C=C1)=CCC1(C)N)=C1)(C=Nc(c2c3)cc(OCCCOc(c(OC)c4)cc(N=C[C@H](C5)N6C=C5c(cc5)ccc5OC)c4C6=O)c3OC)N1C2=O OPVXRHWKTYZKMG-LPYWLSHSSA-N 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780185P | 2013-03-13 | 2013-03-13 | |
| US61/780,185 | 2013-03-13 | ||
| US201361782231P | 2013-03-14 | 2013-03-14 | |
| US61/782,231 | 2013-03-14 | ||
| PCT/US2014/024466 WO2014165119A1 (en) | 2013-03-13 | 2014-03-12 | Cyclodextrin and antibody-drug conjugate formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208020A Division JP2019019140A (ja) | 2013-03-13 | 2018-11-05 | シクロデキストリンおよび抗体−薬物結合体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512540A JP2016512540A (ja) | 2016-04-28 |
| JP2016512540A5 true JP2016512540A5 (https=) | 2017-04-13 |
| JP6463725B2 JP6463725B2 (ja) | 2019-02-06 |
Family
ID=51659070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501545A Expired - Fee Related JP6463725B2 (ja) | 2013-03-13 | 2014-03-12 | シクロデキストリンおよび抗体−薬物結合体製剤 |
| JP2018208020A Withdrawn JP2019019140A (ja) | 2013-03-13 | 2018-11-05 | シクロデキストリンおよび抗体−薬物結合体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208020A Withdrawn JP2019019140A (ja) | 2013-03-13 | 2018-11-05 | シクロデキストリンおよび抗体−薬物結合体製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9610361B2 (https=) |
| EP (1) | EP2970444A4 (https=) |
| JP (2) | JP6463725B2 (https=) |
| KR (3) | KR20210024245A (https=) |
| CN (1) | CN105189546B (https=) |
| AU (2) | AU2014248640B2 (https=) |
| CA (1) | CA2901575C (https=) |
| EA (1) | EA201591710A1 (https=) |
| HK (1) | HK1220698A1 (https=) |
| IL (3) | IL240598B (https=) |
| MX (2) | MX385713B (https=) |
| SG (3) | SG10202009046SA (https=) |
| WO (1) | WO2014165119A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017210621A1 (en) | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| CN108452319A (zh) * | 2017-02-20 | 2018-08-28 | 浙江特瑞思药业股份有限公司 | 靶向cd20的抗体偶联药物制剂 |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| NZ762505A (en) | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| SG11202006510XA (en) | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| BR112021008041A2 (pt) * | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com células imunitárias anti-cd33 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN113631229B (zh) * | 2019-03-25 | 2025-09-23 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| CA3139180A1 (en) * | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| US20240189341A1 (en) * | 2021-06-22 | 2024-06-13 | Remegen Co., Ltd. | Pharmaceutical combination and use thereof |
| CN115969986A (zh) * | 2022-12-30 | 2023-04-18 | 上海药明生物技术有限公司 | 羟丙基β环糊精稳定MMAE类抗体药物偶联物制剂的应用 |
| WO2026034525A1 (ja) * | 2024-08-07 | 2026-02-12 | 東レ株式会社 | 癌の治療および／または予防用医薬組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659696A (en) | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| PT88490B (pt) | 1987-09-14 | 1992-11-30 | Novo Nordisk As | Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos |
| DE68906942T3 (de) | 1988-03-29 | 1999-05-12 | University Of Florida, Gainesville, Fla. | Pharmazeutische Zusammensetzungen für die parenterale Anwendung. |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| DE60132094T3 (de) | 2001-10-26 | 2012-02-02 | Octoplus Polyactive Sciences B.V. | Verfahren zur Herstellung von gereinigten Partikeln |
| DE10361599A1 (de) | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Flüssigformulierung von Antikörperkonjugaten |
| AR046774A1 (es) | 2003-12-24 | 2005-12-21 | Boehringer Ingelheim Pharma | Formulacion liofilizada de conjugados de anticuerpos |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| MX2011005051A (es) | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
| RU2683325C2 (ru) * | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
| US20110207764A1 (en) | 2010-02-23 | 2011-08-25 | Valery Alakhov | Cyclopolysaccharide compositions |
| JP5875083B2 (ja) * | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| CA2795349C (en) | 2010-04-15 | 2016-11-29 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazepine conjugates |
| US8824311B2 (en) * | 2010-09-13 | 2014-09-02 | Blinq Wireless Inc. | System and method for co-channel interference measurement and managed adaptive resource allocation for wireless backhaul |
| JP5826863B2 (ja) | 2011-02-15 | 2015-12-02 | イミュノジェン・インコーポレーテッド | 細胞傷害性ベンゾジアゼピン誘導体 |
| US20120321603A1 (en) | 2011-06-16 | 2012-12-20 | Nayan Patel | Composition and method for stabilization and delivery of therapeutic molecules |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| DK2968494T3 (en) | 2013-03-13 | 2019-03-04 | Seattle Genetics Inc | ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs |
-
2014
- 2014-03-12 AU AU2014248640A patent/AU2014248640B2/en not_active Ceased
- 2014-03-12 KR KR1020217005783A patent/KR20210024245A/ko not_active Ceased
- 2014-03-12 EA EA201591710A patent/EA201591710A1/ru unknown
- 2014-03-12 EP EP14778142.1A patent/EP2970444A4/en not_active Withdrawn
- 2014-03-12 HK HK16108677.5A patent/HK1220698A1/zh unknown
- 2014-03-12 MX MX2015011367A patent/MX385713B/es unknown
- 2014-03-12 WO PCT/US2014/024466 patent/WO2014165119A1/en not_active Ceased
- 2014-03-12 JP JP2016501545A patent/JP6463725B2/ja not_active Expired - Fee Related
- 2014-03-12 CN CN201480015047.3A patent/CN105189546B/zh not_active Expired - Fee Related
- 2014-03-12 SG SG10202009046SA patent/SG10202009046SA/en unknown
- 2014-03-12 US US14/774,372 patent/US9610361B2/en not_active Expired - Fee Related
- 2014-03-12 CA CA2901575A patent/CA2901575C/en active Active
- 2014-03-12 KR KR1020217020721A patent/KR102401525B1/ko not_active Expired - Fee Related
- 2014-03-12 KR KR1020157023840A patent/KR102274714B1/ko not_active Expired - Fee Related
- 2014-03-12 SG SG11201506372RA patent/SG11201506372RA/en unknown
- 2014-03-12 SG SG10201707618TA patent/SG10201707618TA/en unknown
-
2015
- 2015-08-17 IL IL240598A patent/IL240598B/en active IP Right Grant
- 2015-09-02 MX MX2021005426A patent/MX2021005426A/es unknown
-
2017
- 2017-03-09 US US15/454,953 patent/US9987374B2/en active Active
-
2018
- 2018-03-20 AU AU2018201985A patent/AU2018201985B2/en not_active Ceased
- 2018-04-30 US US15/967,276 patent/US10391181B2/en active Active
- 2018-11-05 JP JP2018208020A patent/JP2019019140A/ja not_active Withdrawn
-
2020
- 2020-03-17 IL IL273359A patent/IL273359B/en unknown
-
2021
- 2021-10-25 IL IL287559A patent/IL287559A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512540A5 (https=) | ||
| KR102274714B1 (ko) | 사이클로덱스트린 및 항체-약물 포합체 제형 | |
| CA3107417C (en) | Effective method for manufacturing antibody-drug conjugate | |
| WO2007110339A1 (en) | Anti-igf-1r human monoclonal antibody formulation | |
| BR112020003474A2 (pt) | composição farmacêutica, e, método para produzir uma composição farmacêutica | |
| JP2005530845A (ja) | 抗体を濃縮するための緩衝化処方物およびその使用方法 | |
| TW201028167A (en) | Pharmaceutical composition | |
| JP7177131B2 (ja) | アポトーシスを誘導するための組成物及び方法 | |
| JP2018519303A (ja) | 抗体デュオカルマイシン薬物複合体を含む組成物 | |
| US20220378908A1 (en) | Compositions and methods for minimizing protein loss at low protein concentrations | |
| US10925973B2 (en) | Compositions and methods for using albumin-based nanomedicines | |
| EA043811B1 (ru) | Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство | |
| NZ711020B2 (en) | Cyclodextrin and antibody-drug conjugate formulations | |
| NZ751431B2 (en) | Cyclodextrin and antibody-drug conjugate formulations |